The 36th AICC International Meeting, hosted in Rome from December 2-4, 2024, is a key gathering for the Italian Association for Cancer Research (AICC). This year’s event will focus on critical signaling pathways and their roles in cancer development and treatment innovation. Key themes will include tumor progression, immune modulation, and the latest diagnostic and therapeutic approaches in oncology.
Hawk Biosystems’ Chief Scientific Officer Veronique Calleja and Senior Scientist Cristina Cacho will present a talk titled “Quantification of PD-1/PD-L1 functional engagement by QF-Pro® is a strong predictor of immune checkpoint inhibitors response in NSCLC” on December 4 at 10:40. Collaborating with Cytosens, Hawk Biosystems’ new distribution partner, Veronique and Cristina will discuss QF-Pro® technology’s predictive value in immunotherapy outcomes, particularly in non-small cell lung cancer. The event will highlight Hawk Biosystems’ commitment to pioneering immunotherapy advancements and foster meaningful exchanges on breakthrough cancer diagnostics.
This project has been co-funded by the European Union’s Horizon Europe research and innovation programme under grant agreement Nº101161495.
“Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.”
Stay connected
Subscribe to the HAWK Biosystems newsletter and don’t miss any news about our company, our products, events and much more.
Cookies on this site are used to personalise content and adverts, provide social media features, and analyse traffic. We also share information about your use of our website with our social media, advertising and analytics partners, who may combine it with other information you have provided to them or that they have collected from your use of their services. For more information, please refer to our cookie policy.